A Phase 2 Study of VX-950 in Combination With Peginterferon Alfa-2a (Pegasys), With and Without Ribavirin (Copegus) in Subjects With Hepatitis C
Phase of Trial: Phase II
Latest Information Update: 23 Sep 2014
At a glance
- Drugs Peginterferon alfa-2a; Ribavirin; Telaprevir
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms PROVE-2
- Sponsors Vertex Pharmaceuticals
- 24 Sep 2009 A pooled analysis of data from the PROVE 1 and PROVE 2 trials will be presented in a poster session at AASLD 2009 on Nov 3rd.
- 12 May 2009 Actual end date (1 Jun 2008) added as reported by ClinicalTrials.gov.
- 30 Apr 2009 Primary endpoint results published in New England Journal of Medicine 360: 1839-1850, No. 18, 30 Apr 2009.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History